In the last decades, evidence suggesting the direct or indirect involvement of B cells on
multiple sclerosis (MS) pathogenesis has accumulated. The increased amount of data on …

Since the beginning of vaccination programs against COVID-19 in different countries,
several populations such as patients with specific immunological conditions have been …

The availability of vaccines against the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), provides hope towards mitigation of the coronavirus disease 2019 (COVID …

Neuroimmunological diseases and their treatment compromise the immune system, thereby
increasing the risk of infections and serious illness. Consequently, vaccinations to protect …

Objective: To describe a temporal association between COVID-19 vaccine administration
and multiple sclerosis (MS) relapses. Methods: This case series study was collected in four …

Background Multiple sclerosis (MS) with onset in the setting of acute SARS-CoV-2 virus
infection has been reported, and reactivation of MS following non-mRNA COVID-19 …

Background: Patients with multiple sclerosis (MS) are at increased risk of infection.
Vaccination can mitigate these risks but only if safe and effective in MS patients, including …

The progress in the development of various vaccine platforms against SARS-CoV-2 have
been rather remarkable owing to advancement in molecular and biologic sciences. Most of …

Disease-modifying therapies (DMTs) are widely used in neuroimmunological diseases such
as multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). Although …

An early assessment and immunization of MS patients allows optimizing vaccine responses
and avoiding potential interference with treatment plans. Vaccinations are safe and effective …